CMRA (Comera Life Sciences Holdings) PS Ratio: 0.00 (As of Jul. 05, 2026)


What is Comera Life Sciences Holdings PS Ratio?

Comera Life Sciences Holdings CMRA PS Ratio is 0.00 as of Jul. 05, 2026.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Comera Life Sciences Holdings's share price is $0.0001. Comera Life Sciences Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.05. Hence, Comera Life Sciences Holdings's PS Ratio for today is 0.00.

The historical rank and industry rank for Comera Life Sciences Holdings's PS Ratio or its related term are showing as below:

CMRA's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.93
* Ranked among companies with meaningful PS Ratio only.

Comera Life Sciences Holdings's Revenue per Sharefor the three months ended in Sep. 2023 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.05.

Back to Basics: PS Ratio


Comera Life Sciences Holdings  (OTCPK:CMRA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Comera Life Sciences Holdings PS Ratio Related Terms


Comera Life Sciences Holdings PS Ratio Historical Data

* Premium members only.

The historical data trend for Comera Life Sciences Holdings's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Comera Life Sciences Holdings PS Ratio Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
PS Ratio
0.00 0.00 20.16

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 38.33 20.16 14.27 7.99 5.61

CMRA vs FREQ, BNTC, IMNN: PS Ratio Comparison

For the Biotechnology subindustry, Comera Life Sciences Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Comera Life Sciences Holdings PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's PS Ratio distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's PS Ratio falls into.



Comera Life Sciences Holdings PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Comera Life Sciences Holdings's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0001/0.052
=0.00

Comera Life Sciences Holdings's Share Price of today is $0.0001.
Comera Life Sciences Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 0.00 mean?
Comera Life Sciences Holdings (CMRA) has a PS Ratio of 0.00 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Comera Life Sciences Holdings and its competitors.
Is Comera Life Sciences Holdings' PS Ratio too high?
Comera Life Sciences Holdings' current PS Ratio is 0.00.
How does Comera Life Sciences Holdings' PS Ratio compare to FREQ and BNTC?
Comera Life Sciences Holdings' PS Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.93, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Comera Life Sciences Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Comera Life Sciences Holdings's current PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comera Life Sciences Holdings stock overvalued right now?
Comera Life Sciences Holdings (CMRA) has a current PS Ratio of 0.00. The current PS Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Comera Life Sciences Holdings (CMRA), the current PS Ratio is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Comera Life Sciences Holdings Business Description

Address 12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.